Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Biohaven Pharmaceutical management to meet virrtually with Piper Sandler » 04:55
07/09/20
07/09
04:55
07/09/20
04:55
BHVN

Biohaven Pharmaceutical

$77.99 /

+6.07 (+8.44%)

Virtual Meeting to be…

Virtual Meeting to be held on July 9 hosted by Piper Sandler.

ShowHide Related Items >><<
BHVN Biohaven Pharmaceutical
$77.99 /

+6.07 (+8.44%)

BHVN Biohaven Pharmaceutical
$77.99 /

+6.07 (+8.44%)

07/06/20 Piper Sandler
Biohaven launch of Nurtec 'continues to impress,' says Piper Sandler
06/25/20 Mizuho
Biohaven selloff yesterday a buying opportunity, says Mizuho
06/24/20 Piper Sandler
Piper Sandler stays Overweight Biohaven after troriluzole efficacy signal in OCD
06/23/20 Cantor Fitzgerald
Biohaven Pharmaceutical price target raised to $109 from $82 at Cantor Fitzgerald
BHVN Biohaven Pharmaceutical
$77.99 /

+6.07 (+8.44%)

  • 29
    Jan
BHVN Biohaven Pharmaceutical
$77.99 /

+6.07 (+8.44%)

BHVN Biohaven Pharmaceutical
$77.99 /

+6.07 (+8.44%)

BHVN Biohaven Pharmaceutical
$77.99 /

+6.07 (+8.44%)

Monday
Recommendations
Biohaven launch of Nurtec 'continues to impress,' says Piper Sandler » 05:02
07/06/20
07/06
05:02
07/06/20
05:02
BHVN

Biohaven Pharmaceutical

$71.19 /

-1.075 (-1.49%)

, ABBV

AbbVie

$98.87 /

-0.25 (-0.25%)

Per Iqvia, the latest…

Per Iqvia, the latest Nurtec growth rate was 8%, while AbbVie's (ABBV) Ubrelvy underperformed at 4%, Piper Sandler analyst Tyler Van Buren tells investors in a research note. The analyst believes Biohaven Pharmaceutical's (BHVN) Nurtec "continues to impress" since launch. With patient retention remaining above 40%, satisfied patients are refilling their prescriptions, says Van Buren, who keeps an Overweight rating on Biohaven with a $100 price target.

ShowHide Related Items >><<
BHVN Biohaven Pharmaceutical
$71.19 /

-1.075 (-1.49%)

ABBV AbbVie
$98.87 /

-0.25 (-0.25%)

BHVN Biohaven Pharmaceutical
$71.19 /

-1.075 (-1.49%)

06/25/20 Mizuho
Biohaven selloff yesterday a buying opportunity, says Mizuho
06/24/20 Piper Sandler
Piper Sandler stays Overweight Biohaven after troriluzole efficacy signal in OCD
06/23/20 Cantor Fitzgerald
Biohaven Pharmaceutical price target raised to $109 from $82 at Cantor Fitzgerald
06/19/20 Piper Sandler
Biohaven launch of Nurtec continues to impress, says Piper Sandler
ABBV AbbVie
$98.87 /

-0.25 (-0.25%)

06/29/20 Mizuho
AbbVie price target raised to $110 from $101 at Mizuho
06/26/20 Raymond James
Adverum Biotechnologies downgradedat Raymond James on abicipar CRL
06/25/20 RBC Capital
AbbVie price target raised to $125 from $102 at RBC Capital
06/24/20 BofA
AbbVie Orilissa guidance for 2025 in more jeopardy after Myovant data, says BofA
BHVN Biohaven Pharmaceutical
$71.19 /

-1.075 (-1.49%)

ABBV AbbVie
$98.87 /

-0.25 (-0.25%)

  • 29
    Jan
BHVN Biohaven Pharmaceutical
$71.19 /

-1.075 (-1.49%)

ABBV AbbVie
$98.87 /

-0.25 (-0.25%)

BHVN Biohaven Pharmaceutical
$71.19 /

-1.075 (-1.49%)

ABBV AbbVie
$98.87 /

-0.25 (-0.25%)

BHVN Biohaven Pharmaceutical
$71.19 /

-1.075 (-1.49%)

ABBV AbbVie
$98.87 /

-0.25 (-0.25%)

Conference/Events
Biohaven Pharmaceutical management to meet virtually with Piper Sandler » 04:55
07/06/20
07/06
04:55
07/06/20
04:55
BHVN

Biohaven Pharmaceutical

$71.19 /

-1.075 (-1.49%)

Virtual Meeting to be…

Virtual Meeting to be held on July 6 hosted by Piper Sandler.

ShowHide Related Items >><<
BHVN Biohaven Pharmaceutical
$71.19 /

-1.075 (-1.49%)

BHVN Biohaven Pharmaceutical
$71.19 /

-1.075 (-1.49%)

06/25/20 Mizuho
Biohaven selloff yesterday a buying opportunity, says Mizuho
06/24/20 Piper Sandler
Piper Sandler stays Overweight Biohaven after troriluzole efficacy signal in OCD
06/23/20 Cantor Fitzgerald
Biohaven Pharmaceutical price target raised to $109 from $82 at Cantor Fitzgerald
06/19/20 Piper Sandler
Biohaven launch of Nurtec continues to impress, says Piper Sandler
BHVN Biohaven Pharmaceutical
$71.19 /

-1.075 (-1.49%)

  • 29
    Jan
BHVN Biohaven Pharmaceutical
$71.19 /

-1.075 (-1.49%)

BHVN Biohaven Pharmaceutical
$71.19 /

-1.075 (-1.49%)

BHVN Biohaven Pharmaceutical
$71.19 /

-1.075 (-1.49%)

Over a week ago
Conference/Events
Biohaven Pharmaceutical management to meet virrtually with Piper Sandler » 10:10
07/02/20
07/02
10:10
07/02/20
10:10
BHVN

Biohaven Pharmaceutical

$72.44 /

+0.18 (+0.25%)

Virtual Meeting to be…

Virtual Meeting to be held on July 9 hosted by Piper Sandler.

ShowHide Related Items >><<
BHVN Biohaven Pharmaceutical
$72.44 /

+0.18 (+0.25%)

BHVN Biohaven Pharmaceutical
$72.44 /

+0.18 (+0.25%)

06/25/20 Mizuho
Biohaven selloff yesterday a buying opportunity, says Mizuho
06/24/20 Piper Sandler
Piper Sandler stays Overweight Biohaven after troriluzole efficacy signal in OCD
06/23/20 Cantor Fitzgerald
Biohaven Pharmaceutical price target raised to $109 from $82 at Cantor Fitzgerald
06/19/20 Piper Sandler
Biohaven launch of Nurtec continues to impress, says Piper Sandler
BHVN Biohaven Pharmaceutical
$72.44 /

+0.18 (+0.25%)

  • 29
    Jan
BHVN Biohaven Pharmaceutical
$72.44 /

+0.18 (+0.25%)

BHVN Biohaven Pharmaceutical
$72.44 /

+0.18 (+0.25%)

BHVN Biohaven Pharmaceutical
$72.44 /

+0.18 (+0.25%)

Conference/Events
Biohaven Pharmaceutical management to meet virtually with Piper Sandler » 08:27
06/30/20
06/30
08:27
06/30/20
08:27
BHVN

Biohaven Pharmaceutical

$68.98 /

-0.91 (-1.30%)

Virtual Meeting to be…

Virtual Meeting to be held on July 6 hosted by Piper Sandler.

ShowHide Related Items >><<
BHVN Biohaven Pharmaceutical
$68.98 /

-0.91 (-1.30%)

BHVN Biohaven Pharmaceutical
$68.98 /

-0.91 (-1.30%)

06/25/20 Mizuho
Biohaven selloff yesterday a buying opportunity, says Mizuho
06/24/20 Piper Sandler
Piper Sandler stays Overweight Biohaven after troriluzole efficacy signal in OCD
06/23/20 Cantor Fitzgerald
Biohaven Pharmaceutical price target raised to $109 from $82 at Cantor Fitzgerald
06/19/20 Piper Sandler
Biohaven launch of Nurtec continues to impress, says Piper Sandler
BHVN Biohaven Pharmaceutical
$68.98 /

-0.91 (-1.30%)

  • 29
    Jan
BHVN Biohaven Pharmaceutical
$68.98 /

-0.91 (-1.30%)

BHVN Biohaven Pharmaceutical
$68.98 /

-0.91 (-1.30%)

BHVN Biohaven Pharmaceutical
$68.98 /

-0.91 (-1.30%)

Recommendations
Biohaven selloff yesterday a buying opportunity, says Mizuho » 06:45
06/25/20
06/25
06:45
06/25/20
06:45
BHVN

Biohaven Pharmaceutical

$70.09 /

-2.775 (-3.81%)

Mizuho analyst Vamil…

Mizuho analyst Vamil Divan recommends using the selloff yesterday in shares of Biohaven Pharmaceutical as a buying opportunity. The company released "mixed" topline data for the Phase 2/3 study of troriluzole in obsessive compulsive disorder as the drug missed the primary endpoint but did show a trend to benefit, especially in patients with more severe disease, Divan tells investors in a research note. While the company plans to move forward with a larger Phase 3 program, the analyst expects investor focus on the stock to remain on the "strong progress" with Nurtec ODT. Divan expects Nurtec ODT to continue to exceed expectations and keeps a Buy rating on Biohaven with an $85 price target.

ShowHide Related Items >><<
BHVN Biohaven Pharmaceutical
$70.09 /

-2.775 (-3.81%)

BHVN Biohaven Pharmaceutical
$70.09 /

-2.775 (-3.81%)

06/24/20 Piper Sandler
Piper Sandler stays Overweight Biohaven after troriluzole efficacy signal in OCD
06/23/20 Cantor Fitzgerald
Biohaven Pharmaceutical price target raised to $109 from $82 at Cantor Fitzgerald
06/19/20 Piper Sandler
Biohaven launch of Nurtec continues to impress, says Piper Sandler
06/18/20 Wedbush
Biohaven Pharmaceutical price target raised to $94 from $74 at Wedbush
BHVN Biohaven Pharmaceutical
$70.09 /

-2.775 (-3.81%)

BHVN Biohaven Pharmaceutical
$70.09 /

-2.775 (-3.81%)

BHVN Biohaven Pharmaceutical
$70.09 /

-2.775 (-3.81%)

BHVN Biohaven Pharmaceutical
$70.09 /

-2.775 (-3.81%)

Conference/Events
Biohaven Pharmaceutical management to meet virtually with Mizuho » 04:55
06/25/20
06/25
04:55
06/25/20
04:55
BHVN

Biohaven Pharmaceutical

$70.09 /

-2.775 (-3.81%)

Virtual Meeting to be…

Virtual Meeting to be held on June 25 hosted by Mizuho.

ShowHide Related Items >><<
BHVN Biohaven Pharmaceutical
$70.09 /

-2.775 (-3.81%)

BHVN Biohaven Pharmaceutical
$70.09 /

-2.775 (-3.81%)

06/24/20 Piper Sandler
Piper Sandler stays Overweight Biohaven after troriluzole efficacy signal in OCD
06/23/20 Cantor Fitzgerald
Biohaven Pharmaceutical price target raised to $109 from $82 at Cantor Fitzgerald
06/19/20 Piper Sandler
Biohaven launch of Nurtec continues to impress, says Piper Sandler
06/18/20 Wedbush
Biohaven Pharmaceutical price target raised to $94 from $74 at Wedbush
BHVN Biohaven Pharmaceutical
$70.09 /

-2.775 (-3.81%)

BHVN Biohaven Pharmaceutical
$70.09 /

-2.775 (-3.81%)

BHVN Biohaven Pharmaceutical
$70.09 /

-2.775 (-3.81%)

BHVN Biohaven Pharmaceutical
$70.09 /

-2.775 (-3.81%)

Recommendations
Piper Sandler stays Overweight Biohaven after troriluzole efficacy signal in OCD » 10:14
06/24/20
06/24
10:14
06/24/20
10:14
BHVN

Biohaven Pharmaceutical

$69.17 /

-3.695 (-5.07%)

Piper Sandler analyst…

Piper Sandler analyst Tyler Van Buren reiterates his Overweight rating on Biohaven Pharmaceutical after the company reported the emergence of an efficacy signal for troriluzole from a Phase II/III trial in Obsessive-Compulsive Disorder, or OCD, patients. While the trial endpoint did not reach significance at 12 weeks due to a higher placebo effect, management stated that the lack of statistical significance was primarily driven by the adaptive study design that wasn't powered or intended to lessen placebo effects, Van Buren noted. In Phase III, Biohaven will be increasing the dose, improving the trial design to limit placebo response, and increasing the powering, noted the analyst, who sees a "SSRI-like potential market opportunity" given a market with 2 million OCD patients.

ShowHide Related Items >><<
BHVN Biohaven Pharmaceutical
$69.17 /

-3.695 (-5.07%)

BHVN Biohaven Pharmaceutical
$69.17 /

-3.695 (-5.07%)

06/23/20 Cantor Fitzgerald
Biohaven Pharmaceutical price target raised to $109 from $82 at Cantor Fitzgerald
06/19/20 Piper Sandler
Biohaven launch of Nurtec continues to impress, says Piper Sandler
06/18/20 Wedbush
Biohaven Pharmaceutical price target raised to $94 from $74 at Wedbush
06/15/20 Cowen
Biohaven Pharmaceutical price target raised to $80 from $60 at Cowen
BHVN Biohaven Pharmaceutical
$69.17 /

-3.695 (-5.07%)

BHVN Biohaven Pharmaceutical
$69.17 /

-3.695 (-5.07%)

BHVN Biohaven Pharmaceutical
$69.17 /

-3.695 (-5.07%)

BHVN Biohaven Pharmaceutical
$69.17 /

-3.695 (-5.07%)

Hot Stocks
Biohaven Pharmaceutical's troriluzole in OCD did not meet primary endpoint » 07:10
06/24/20
06/24
07:10
06/24/20
07:10
BHVN

Biohaven Pharmaceutical

$72.87 /

-0.685 (-0.93%)

Biohaven Pharmaceutical…

Biohaven Pharmaceutical reported topline results from its proof of concept study of troriluzole in the treatment of obsessive-compulsive disorder, or OCD. Troriluzole treated subjects had a mean Yale-Brown Obsessive Compulsive Scale improvement of -5.1 points from baseline versus -3.6 for placebo-treated subjects at week 8, and -5.9 points versus -4.9 for placebo subjects at week 12. Although the p-value in this proof of concept study did not reach statistical significance at the primary Y-BOCS endpoint at week 12, the results reveal a "consistent" treatment benefit of troriluzole over time and provide the appropriate data to power future studies. Troriluzole treatment differences compared to placebo were greater in patients who were more severely ill at baseline. Obsessive-compulsive disorder is a serious psychiatric condition affecting over 2 million individuals in the U.S. and significantly impacts quality of life. Completion of the trial for troriluzole in Alzheimer's Disease trial is expected in Q4, and topline data from the troriluzole in SCA trial are anticipated in 2021.

ShowHide Related Items >><<
BHVN Biohaven Pharmaceutical
$72.87 /

-0.685 (-0.93%)

BHVN Biohaven Pharmaceutical
$72.87 /

-0.685 (-0.93%)

06/23/20 Cantor Fitzgerald
Biohaven Pharmaceutical price target raised to $109 from $82 at Cantor Fitzgerald
06/19/20 Piper Sandler
Biohaven launch of Nurtec continues to impress, says Piper Sandler
06/18/20 Wedbush
Biohaven Pharmaceutical price target raised to $94 from $74 at Wedbush
06/15/20 Cowen
Biohaven Pharmaceutical price target raised to $80 from $60 at Cowen
BHVN Biohaven Pharmaceutical
$72.87 /

-0.685 (-0.93%)

BHVN Biohaven Pharmaceutical
$72.87 /

-0.685 (-0.93%)

BHVN Biohaven Pharmaceutical
$72.87 /

-0.685 (-0.93%)

BHVN Biohaven Pharmaceutical
$72.87 /

-0.685 (-0.93%)

Conference/Events
Biohaven Pharmaceutical management to meet virtually with Mizuho » 08:51
06/23/20
06/23
08:51
06/23/20
08:51
BHVN

Biohaven Pharmaceutical

$73.55 /

+1.22 (+1.69%)

Virtual Meeting to be…

Virtual Meeting to be held on June 25 hosted by Mizuho.

ShowHide Related Items >><<
BHVN Biohaven Pharmaceutical
$73.55 /

+1.22 (+1.69%)

BHVN Biohaven Pharmaceutical
$73.55 /

+1.22 (+1.69%)

06/23/20 Cantor Fitzgerald
Biohaven Pharmaceutical price target raised to $109 from $82 at Cantor Fitzgerald
06/19/20 Piper Sandler
Biohaven launch of Nurtec continues to impress, says Piper Sandler
06/18/20 Wedbush
Biohaven Pharmaceutical price target raised to $94 from $74 at Wedbush
06/15/20 Cowen
Biohaven Pharmaceutical price target raised to $80 from $60 at Cowen
BHVN Biohaven Pharmaceutical
$73.55 /

+1.22 (+1.69%)

BHVN Biohaven Pharmaceutical
$73.55 /

+1.22 (+1.69%)

BHVN Biohaven Pharmaceutical
$73.55 /

+1.22 (+1.69%)

BHVN Biohaven Pharmaceutical
$73.55 /

+1.22 (+1.69%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.